$1 billion market cap at $1 per share...., page-17

Kakoii

Just a minor point in relation to the Vermillion announcement.

Their product is a diagnostic for O.C. not a treatment.

Yes there are other companies on the trail of developing treatments, but Cvac is the closest to completion of an immunotherapy treatment, having had the path beaten in this field by Provenge.

"About OVA1OVA1 was the first FDA-cleared blood test for pre-surgical cancer diagnosis that achieved 99% accuracy in clinical trials for detecting epithelial ovarian cancers.(1) In other studies, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(2) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(3) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics."